Related Experiment Video

Updated: May 26, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines

Anatasha Crawford1, Rita Nahta

  • 1Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA.

Current Pharmacogenomics and Personalized Medicine
|December 14, 2011
PubMed

Insights

Acquired Herceptin resistance in breast cancer involves increased Bcl-2 protein levels. Inhibiting Bcl-2 or PI3K/IKK pathways can restore Herceptin sensitivity, suggesting Bcl-2 as a therapeutic target and response predictor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Acquired resistance to Herceptin (trastuzumab) is a significant clinical challenge in treating HER2-overexpressing breast cancer.
  • Understanding resistance mechanisms is crucial for identifying new therapeutic targets and predicting treatment outcomes.
  • While anti-apoptotic proteins are linked to resistance to other HER2-targeted drugs like lapatinib, their role in Herceptin resistance is less understood.

Purpose of the Study:

  • To investigate the role of the anti-apoptotic protein Bcl-2 in acquired Herceptin resistance in HER2-overexpressing breast cancer.
  • To determine if Bcl-2 is a potential therapeutic target for overcoming Herceptin resistance.
  • To explore the potential of Bcl-2 expression as a predictive biomarker for Herceptin response.

Main Methods:

  • Utilized BT474 HER2-overexpressing breast cancer cell line and derived Herceptin-resistant clones.
  • Assessed Bcl-2 and Bax protein expression using Western blotting.
  • Evaluated cell proliferation in response to Bcl-2 inhibitor ABT-737 and Herceptin.
  • Examined the impact of PI3K and IKK inhibition on Bcl-2 expression and Herceptin sensitivity.

Main Results:

  • Cells with acquired Herceptin resistance exhibited an elevated Bcl-2:Bax protein ratio.
  • Herceptin-resistant cells showed increased sensitivity to the Bcl-2 inhibitor ABT-737.
  • Pharmacological inhibition of Bcl-2 restored sensitivity to Herceptin in resistant cells.
  • Inhibition of PI3K or IKK pathways led to down-regulation of Bcl-2 and enhanced Herceptin sensitivity.

Conclusions:

  • Increased Bcl-2:Bax ratio is associated with acquired Herceptin resistance in HER2-overexpressing breast cancer.
  • Targeting Bcl-2 with inhibitors like ABT-737 can re-sensitize resistant cells to Herceptin.
  • PI3K and IKK pathways modulate Bcl-2 expression and influence Herceptin sensitivity, presenting them as potential therapeutic targets.
  • Bcl-2 expression warrants further investigation as a predictive biomarker for Herceptin response in patients.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...